Research ExplorerPublicationsUp-regulation of Biglycan is Associated with Poor Prognosis ...

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer

Standard

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. / Jacobsen, Frank; Kraft, Juliane; Schroeder, Cornelia; Hube-Magg, Claudia; Kluth, Martina; Lang, Dagmar S; Simon, Ronald; Sauter, Guido; Izbicki, Jakob R; Clauditz, Till S; Luebke, Andreas M; Hinsch, Andrea; Wilczak, Waldemar; Wittmer, Corinna; Büscheck, Franziska; Höflmayer, Doris; Minner, Sarah; Tsourlakis, Maria Christina; Huland, Hartwig; Graefen, Markus; Budäus, Lars; Thederan, Imke; Salomon, Georg; Schlomm, Thorsten; Melling, Nathaniel.

In: NEOPLASIA, Vol. 19, No. 9, 09.2017, p. 707-715.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Jacobsen, F, Kraft, J, Schroeder, C, Hube-Magg, C, Kluth, M, Lang, DS, Simon, R, Sauter, G, Izbicki, JR, Clauditz, TS, Luebke, AM, Hinsch, A, Wilczak, W, Wittmer, C, Büscheck, F, Höflmayer, D, Minner, S, Tsourlakis, MC, Huland, H, Graefen, M, Budäus, L, Thederan, I, Salomon, G, Schlomm, T & Melling, N 2017, 'Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer', NEOPLASIA, vol. 19, no. 9, pp. 707-715. https://doi.org/10.1016/j.neo.2017.06.003

APA

Jacobsen, F., Kraft, J., Schroeder, C., Hube-Magg, C., Kluth, M., Lang, D. S., Simon, R., Sauter, G., Izbicki, J. R., Clauditz, T. S., Luebke, A. M., Hinsch, A., Wilczak, W., Wittmer, C., Büscheck, F., Höflmayer, D., Minner, S., Tsourlakis, M. C., Huland, H., ... Melling, N. (2017). Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. NEOPLASIA, 19(9), 707-715. https://doi.org/10.1016/j.neo.2017.06.003

Vancouver

Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang DS et al. Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. NEOPLASIA. 2017 Sep;19(9):707-715. https://doi.org/10.1016/j.neo.2017.06.003

Bibtex

@article{7d8e902e91b244849a17a5b3b3c19424,
title = "Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer",
abstract = "Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence (P<.0001 each). Comparison with our molecular database attached to the TMA revealed that BGN expression was linked to presence of TMPRRS2:ERG fusion and PTEN deletion (P<.0001 each). In addition, BGN was strongly linked to androgen-receptor (AR) levels (P<.0001), suggesting a hormone-depending regulation of BGN. BGN up-regulation is a frequent feature of prostate cancer that parallels tumor progression and may be useful to estimate tumor aggressiveness particularly if combined with other molecular markers.",
keywords = "Journal Article",
author = "Frank Jacobsen and Juliane Kraft and Cornelia Schroeder and Claudia Hube-Magg and Martina Kluth and Lang, {Dagmar S} and Ronald Simon and Guido Sauter and Izbicki, {Jakob R} and Clauditz, {Till S} and Luebke, {Andreas M} and Andrea Hinsch and Waldemar Wilczak and Corinna Wittmer and Franziska B{\"u}scheck and Doris H{\"o}flmayer and Sarah Minner and Tsourlakis, {Maria Christina} and Hartwig Huland and Markus Graefen and Lars Bud{\"a}us and Imke Thederan and Georg Salomon and Thorsten Schlomm and Nathaniel Melling",
note = "Copyright {\textcopyright} 2017 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2017",
month = sep,
doi = "10.1016/j.neo.2017.06.003",
language = "English",
volume = "19",
pages = "707--715",
journal = "NEOPLASIA",
issn = "1476-5586",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer

AU - Jacobsen, Frank

AU - Kraft, Juliane

AU - Schroeder, Cornelia

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Lang, Dagmar S

AU - Simon, Ronald

AU - Sauter, Guido

AU - Izbicki, Jakob R

AU - Clauditz, Till S

AU - Luebke, Andreas M

AU - Hinsch, Andrea

AU - Wilczak, Waldemar

AU - Wittmer, Corinna

AU - Büscheck, Franziska

AU - Höflmayer, Doris

AU - Minner, Sarah

AU - Tsourlakis, Maria Christina

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Budäus, Lars

AU - Thederan, Imke

AU - Salomon, Georg

AU - Schlomm, Thorsten

AU - Melling, Nathaniel

N1 - Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2017/9

Y1 - 2017/9

N2 - Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence (P<.0001 each). Comparison with our molecular database attached to the TMA revealed that BGN expression was linked to presence of TMPRRS2:ERG fusion and PTEN deletion (P<.0001 each). In addition, BGN was strongly linked to androgen-receptor (AR) levels (P<.0001), suggesting a hormone-depending regulation of BGN. BGN up-regulation is a frequent feature of prostate cancer that parallels tumor progression and may be useful to estimate tumor aggressiveness particularly if combined with other molecular markers.

AB - Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence (P<.0001 each). Comparison with our molecular database attached to the TMA revealed that BGN expression was linked to presence of TMPRRS2:ERG fusion and PTEN deletion (P<.0001 each). In addition, BGN was strongly linked to androgen-receptor (AR) levels (P<.0001), suggesting a hormone-depending regulation of BGN. BGN up-regulation is a frequent feature of prostate cancer that parallels tumor progression and may be useful to estimate tumor aggressiveness particularly if combined with other molecular markers.

KW - Journal Article

U2 - 10.1016/j.neo.2017.06.003

DO - 10.1016/j.neo.2017.06.003

M3 - SCORING: Journal article

C2 - 28830008

VL - 19

SP - 707

EP - 715

JO - NEOPLASIA

JF - NEOPLASIA

SN - 1476-5586

IS - 9

ER -